Pulmonary Fibrosis Foundation selects UofL for newly established Care Center Network

NewsGuard 100/100 Score

The University of Louisville is one of nine pilot sites selected by the Pulmonary Fibrosis Foundation (PFF) for its newly established Care Center Network and the PFF Patient Registry program. Rafael Perez, M.D., director of the UofL Interstitial Lung Disease (ILD) program in the Division of Pulmonary, Critical Care & Sleep Disorders Medicine, will lead the UofL site.

Aimed at improving the health and quality of life of patients suffering from pulmonary fibrosis, the network and registry will help provide critical insights enabling the medical research community to develop more effective therapies, say UofL physicians involved in the initiative.

Sites were selected because of their expertise in pulmonary fibrosis patient care and research. In the network with UofL are the University of California, San Francisco, University of Chicago, University of Michigan, National Jewish Health, University of Pittsburgh, Vanderbilt University, University of Washington and Yale University.

"The creation of the registry is a great step forward by the PFF," said Jesse Roman, M.D., chair of UofL's Department of Medicine. "The benefits to patients are that they can contribute to the endeavor and partner with us in identifying new areas for intervention. In short, they become an integral part of their care—they truly are the essence of the network."

Affecting up to 200,000 people in the United States, pulmonary fibrosis is a condition in which lung tissue becomes thickened, stiff and scarred. In most cases, there is no known cause and the disease is termed idiopathic pulmonary fibrosis. The lung damage caused by pulmonary fibrosis cannot be reversed, and while there are medications that can help ease symptoms, there is no cure.

The disease is relentlessly progressive; patients almost always die within two to five years of diagnosis. Annually, 40,000 people die from pulmonary fibrosis - the same number of deaths caused by breast cancer each year.

"To make progress with this disease, we need a multidisciplinary approach by teams of expert medical professionals, we need more data, and we need to track the natural history of the disease," said Daniel M. Rose, M.D., CEO and board chair of the PFF. "The PFF Care Center Network and Patient Registry will provide these critical cornerstones for improved patient care and progress towards a cure."

The PFF Care Center Network will provide a standardized, multidisciplinary approach to patient care. This model of comprehensive patient care will help identify and establish best practices, determine the impact of specific interventions, and improve the quality of life of patients. The Care Center Network will incrementally expand to eventually include 40 medical centers by 2015.

The PFF Patient Registry is planned to be the largest database of PF patient records with the furthest demographic reach in the country. It will provide data essential for improving the understanding of the epidemiology, incidence, prevalence, natural history, and other clinical characteristics of PF. The registry will use consistent data-gathering methodology so that the information obtained will be useful to all clinicians and researchers seeking to better understand the disease and develop new therapies for PF.

All the pilot sites of the Care Center Network will participate in the Patient Registry. A principal investigator at each network site will work with a team of allied health professionals to enroll PF patients into the Registry. The Duke Clinical Research Institute at Duke University will host and maintain and oversee implementation of the PFF Patient Registry.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Morphine shows potential as effective cough therapy for pulmonary fibrosis, study finds